Latest Industry Insights

In this interview, Dr. Mason tells us about her career path and experiences along the way, as well as sharing advice for women considering a career in science.

In this interview, John Finn tells us more about PGI, how it compares to other genome editing approaches and the benefits it could bring to genomic medicine discovery.

As the use of generative AI tools expands, and their potential in scientific research is better understood, there are ethical considerations to be made. Dr. Dror Kolodkin-Gal explores some of the issues and potential solutions.

Bio-Rad's Jeremiah McDole explores the benefits of bringing molecular testing in-house and how ddPCR technology can be applied in oncology workflows.

In this interview, James Brayer delves into some of the current obstacles hindering the widespread adoption of genomic medicine and highlights how nanopore-based sequencing can help to address them.

We spoke to Amit Patel, product marketing director at PacBio, to learn more about PacBio Compatible, the new collaborations and what benefits they will bring to customers.

A recent study has shown the clinical value of proactive, sequencing-based screening in apparently healthy newborns for medically actionable conditions. How might these findings impact the current NBS landscape and what does it mean to the healthcare system on the global level?

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

Robert Balog describes innovations in microarray testing technology that are contributing to faster turnaround times, automated interpretation and improved coverage.

This article discusses how the culture of canine-derived organoid lines can be used to make meaningful observations in the emerging field of comparative oncology, prompting the next revolution in animal and human cancer studies.